European Union ruling on medicines in children

摘要

Ursula Creutzig, University Children's Hospital, Muenster, Germany, says: "We hope that our phase 111 trials, which ensure close observation, adverse-event monitoring, and quality control in the total group of patients with a specific form of cancer will be supported".She adds: "Due to the small number of patients it will not be possible to do phase I or II studies in a reasonable timeframe for each off-label drug, which has been in use for manyyears".